Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation

Study Overview
=================
Brief Summary
-----------------
Uterine arteriovenous malformations (UAVM) are short circuits between systemic arterial and venous networks within the uterus. They are congenital or acquired (in the course of an endo-uterine gesture such as curettage or interventions such as caesareans or myomectomies). They can be manifested by severe metrorrhagia that can go as far as to put the patient's vital prognosis at risk. There are no recommendations for the management of UAVM since this pathology is rare and therefore series are performed with few cases. If some of these UAVM disappear spontaneously after a therapeutic abstention, when the clinical context allows it, in case of symptomatic UAVM, a selective embolization with arteriography is often carried out to postpone the hysterectomy of hemostasis. There are also more marginal management options such as Gonadotropin-Releasing Hormone agonists, methotrexate or curettage that are decided on a case by case basis depending on the symptoms and protocols of each medical team. Regarding subsequent fertility and pregnancy outcomes after conservative treatment, the number of studies is even lower.

Official Title
-----------------
Fertility After Diagnosis and Management of Acquired Uterine Arteriovenous Malformation

Conditions
-----------------
Arteriovenous Malformations

Intervention / Treatment
-----------------
* Other: Telephone interview


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Major patient Diagnosis of UAVM, symptomatic or not, between January 1st, 2000 and March 30th, 2017 confirmed by imagery performed at the Rennes University Hospital Not against her participation in research Exclusion Criteria: Minor patient at the time of diagnosis congenital UAVM Uterine malformation Patient under legal protection (guardianship, curatorship, safeguard of justice).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with UAVM<br>All patients who have been diagnosed with UAVM (symptomatic or non-symptomatic) between January 1, 2000 and March 30, 2017, and confirmed by an imaging examination. Telephone interview | Other: Telephone interview<br>* Patients are contacted by telephone to know the history of the disease since the diagnosis of UAVM and the impact of management on fertility. All medical data related to the care and necessary for the study are collected from the medical file the participation of the patients is limited to a telephone interview.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of fertility | The telephone interview seeks to assess fertility for all patients diagnosed with symptomatic or non-symptomatic UAVM regardless of initial management. | At the time of inclusion | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pregnancy outcomes after UAVM | The telephone interview allows to evaluate pregnancy outcomes after diagnosis of UAVM regardless of initial management, in terms of live birth (full term or preterm birth), stillbirth, spontaneous abortion, and induced abortion. | At the time of inclusion | 
| Term of delivery after UAVM | The telephone interview allows to evaluate the term of delivery after diagnosis of UAVM regardless of initial management | At the time of inclusion | 
| Side effects of treatments for UAVM | The telephone interview allows to inventory the side effects of treatments | At the time of inclusion | 
| Complications of treatments for UAVM | The telephone interview allows to evaluate the complications of treatments | At the time of inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Uterine AVM